Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development
CPT: Pharmacometrics & Systems Pharmacology · 2024-05 · 13 (5) · 691-709
DOI: 10.1002/psp4.13079 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 21.03.2024. Verfasst von Wei Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA. Hauptthemen laut MEDLINE: Drug Development, Antineoplastic Agents, Neoplasms, United States Food and Drug Administration. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Project Optimus is a US Food and Drug Administration Oncology Center of Excellence initiative aimed at reforming the dose selection and optimization paradigm in oncology drug development. This project seeks to bring together pharmaceutical companies, international regulatory agencies, academic institutions, patient advocates, and other stakeholders. Although there is much promise in this initiative, there are several challenges that need to be addressed, including multidimensionality of the dose optimization problem in oncology, the heterogeneity of cancer and patients, importance of evaluating long‐term tolerability beyond dose‐limiting toxicities, and the lack of reliable biomarkers for long‐term efficacy. Through the lens of Totality of Evidence and with the mindset of model‐informed drug development, we offer insights into dose optimization by building a quantitative knowledge base integrating diverse sources of data and leveraging quantitative modeling tools to build evidence for drug dosage considering exposure, disease biology, efficacy, toxicity, and patient factors. We believe that rational dose optimization can be achieved in oncology drug development, improving patient outcomes by maximizing therapeutic benefit while minimizing toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA.
- Food and Drug Administration, Silver Spring, Maryland, USA.
- Quantitative Systems Pharmacology, Pfizer, San Diego, California, USA.
- Clinical Pharmacology, Pfizer, San Diego, California, USA.
- Pharmacometrics, Pfizer, Groton, Connecticut, USA.
- Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Wei Gao, Karthik Venkatakrishnan, Yanguang Cao
Zitieren
APA
Gao, W., Liu, J., Shtylla, B., Venkatakrishnan, K., Yin, D., Shah, M., Nicholas, T., & Cao, Y. (2024). Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development. CPT: Pharmacometrics & Systems Pharmacology, 13(5), 691-709. https://doi.org/10.1002/psp4.13079
Vancouver
Gao W, Liu J, Shtylla B, Venkatakrishnan K, Yin D, Shah M, et al. Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(5):691-709. doi:10.1002/psp4.13079
BibTeX
@article{Gao2024,
author = {Gao, Wei and Liu, Jiang and Shtylla, Blerta and Venkatakrishnan, Karthik and Yin, Donghua and Shah, Mirat and Nicholas, Timothy and Cao, Yanguang},
title = {Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
volume = {13},
number = {5},
pages = {691--709},
doi = {10.1002/psp4.13079}
}
EUVIMED